A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery

25Citations
Citations of this article
93Readers
Mendeley users who have this article in their library.

Abstract

The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P0) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task. © 2013 Jiménez-Díaz et al.

Figures

  • Figure 1. Concept of PNSA in vivo assays. Comparison of the theoretical growth curves of Plasmodium berghei upon intravenous infection at day 0 under (A) a Peters’ 4-day test-type or (B) the PNSA assay format for the evaluation of the antimalarial efficacy of drugs. The solid curves represent the growth of parasites treated with vehicle. The dotted lines represent the growth of parasites under arbitrary treatments (6n, denotes arbitrary number of drug dosages) leading to ED50, ED90 and ED99, respectively. The parasitemia that marks the limit between net growth and net clearance of the parasite circulating in peripheral blood is denoted as the NG line. The limit of quantification of parasitemia is denoted as the LQ line. PRR is the parasite reduction ratio, i.e. the ratio of the baseline parasite count to that following treatment. doi:10.1371/journal.pone.0066967.g001
  • Figure 2. Selection of the infective dose for the Plasmodium berghei ED90-normalized in vivo assay. Growth kinetics of P. berghei following intravenous infection of (A) immunocompetent CD1 or (B) immunodeficient NSG mice is shown. The plots show the parasitemia in peripheral blood of female mice infected with 0.16106, 16106, 106106, and 506106 infected erythrocytes. The dashed line (P0) indicates the target human-equivalent parasitemia. Data are the mean 6 standard deviation of n = 4 mice/group. Error bars are shown only if they are bigger than symbols. doi:10.1371/journal.pone.0066967.g002
  • Figure 3. Plasmodium berghei clearance upon antimalarial treatment. The plots show the kinetics of parasitemia in peripheral blood of CD1 female mice infected with 106106 infected erythrocytes at day 0 and treated at days 2 and 3 (downward arrows) with a set of antimalarial drugs used for validation of the P. berghei ED90-normalized in vivo assay. For clarity, only selected doses are explicitly indicated in the plot. Data are the mean 6 standard deviation of n = 3 mice/group. Error bars are shown only if they are bigger than symbols. doi:10.1371/journal.pone.0066967.g003
  • Figure 4. Best-fit dose–response curve. The plot shows the log10 [parasitemia at day 4] versus log10 [dose administered in mg/kg] of a set of antimalarial drugs used for validation of the Plasmodium berghei ED90-normalized in vivo assay. A minimum of five dose levels of each drug were used to fit the dose–response functions. The dotted line indicates the mean ED90 estimated for each drug. doi:10.1371/journal.pone.0066967.g004
  • Figure 5. Analysis of parasite reduction ratio at 48 h (PRR48h). Evaluation of PRR48h allowed validation of the Plasmodium berghei ED90normalized in vivo assay in vehicle-treated control animals and against human data. (A) Correlation between the log10 [PRR48h] and the distance between top and bottom values of the logistic fit calculated in Figure 4 for each control antimalarial in CD1 mice infected with P. berghei. (B) Correlation of log10 [PRR48h] between CD1 mice infected with P. berghei in the screening assay format and humans infected with P. falciparum. Data on log10 [PRR48h] in humans are taken from [30–32]. doi:10.1371/journal.pone.0066967.g005
  • Table 1. Comparison of the in vivo potency of a set antimalarial drugs in the ED90-normalized assay versus the Peters’ 4-day test.
  • Figure 6. Screening of in vitro hits from TCAMS in the Plasmodium berghei ED90-normalized in vivo assay. (A) A collection of 590 compounds were screened at 50 mg/kg in 20% CaptisolH given orally (open circles, open diamonds, open triangles). The series consisted of a first experiment of 50 compounds followed by 5 experiments of 100 compounds each and three additional experiments with 20, 7, and 13 compounds, respectively. Each experiment included a control group treated with vehicle (closed diamond) as a reference to calculate the percentage of inhibition of parasitemia in peripheral blood (dotted line). The response of standard antimalarials in the same assay is also presented (closed circles). Data shown are the mean log10 [parasitemia at day 4] of two mice per point. Open squares indicate compounds with YOYO-1530/585 flow cytometry patterns similar to chloroquine (CQ-like, potential fast killing compounds) whereas open triangles mark compounds with patterns similar to pyrimethamine (Pyr-like, potential non-fast killing compounds). (B) Patterns of YOYO-1530/585 flow cytometry method at day 4 for vehicle-, chloroquine- and, pyrimethamine-treated mice. doi:10.1371/journal.pone.0066967.g006
  • Figure 7. A new paradigm for the critical path of compound progression in antimalarial drug discovery. Compounds with activity in in vitro phenotypic assays are rigorously scored according to available in silico/in vitro absorption, distribution, metabolism and toxicity (ADMET) predictive techniques and theoretical chemical properties. Small amounts of compound (10 mg) are synthesized in order of priority for in vivo screening in the Plasmodium berghei ED90-normalized assay. Non-efficacious compounds showing significant exposure could be rescued for retesting in the P. falciparum humanized mouse (HuMouse) model in order to discard the risk of species selectivity. Efficacious compounds are evaluated in vitro for drug metabolism/pharmacokinetics (DMPK), toxicity, and anti-parasitic activity for identification of development risks. The lead optimization program commences with full profiling of the lead compound: in vitro cytotoxicity and preliminary genotoxicity, in vivo DMPK (bioavailability and clearance in rodents), in vitro generation of resistance and killing rate activity, and in vivo dose–response efficacy in the P. falciparum HuMouse model. Further enrichment of the outcome of the P. berghei in vivo screening can be obtained by coupling high-content secondary endpoints to the screening, such as snapshot pharmacokinetic sampling, to provide valuable information for validation and refinement of ADMET predictive tools. doi:10.1371/journal.pone.0066967.g007

References Powered by Scopus

2748Citations
1233Readers
Get full text
1442Citations
1542Readers
Get full text

Cited by Powered by Scopus

This article is free to access.

Get full text

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jiménez-Díaz, M. B., Viera, S., Ibáñez, J., Mulet, T., Magán-Marchal, N., Garuti, H., … Angulo-Barturen, I. (2013). A New In Vivo Screening Paradigm to Accelerate Antimalarial Drug Discovery. PLoS ONE, 8(6). https://doi.org/10.1371/journal.pone.0066967

Readers over time

‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 32

51%

Researcher 23

37%

Professor / Associate Prof. 4

6%

Lecturer / Post doc 4

6%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 20

36%

Pharmacology, Toxicology and Pharmaceut... 14

25%

Chemistry 11

20%

Biochemistry, Genetics and Molecular Bi... 10

18%

Save time finding and organizing research with Mendeley

Sign up for free
0